Deepak Khanna, Senior Vice President and MSD UK Managing Director, has been named as President Elect of the Association of the British Pharmaceutical Industry (ABPI).
08 Dec 2011 Posted in News Release By Communications
Taking over from current ABPI President Simon Jose of GSK after the 2012 ABPI AGM in April, Deepak, who will initially serve for one year, with the option of re-election for a further 12 months, said:
"I am absolutely delighted and deeply honoured to have been given the opportunity to lead the representation of the industry at this challenging time for the pharmaceutical sector. The Government's proposals for a new pricing system for branded medicines, the reforms of the NHS, and the recommendations of the Nicholson Review of Innovation mean it is vital for the industry to have a strong and united voice.
"Innovative medicines play an important role in meeting the needs of patients, helping the NHS to improve health outcomes, and supporting the growth of the economy. I am looking forward to working with the Government, the NHS, patient groups and life science companies to ensure that the industry continues to make a significant contribution to the health and wealth of the UK."
Deepak, who began his career with Merck in 1988, previously managed all aspects of the US Merck/Schering-Plough Joint Venture, and was responsible for the US marketing and sales for the two cardiovascular products jointly marketed by the two companies. After the announcement of plans to merge with Schering-Plough (March 2009), Mr Khanna also led the US integration planning efforts.
Mr Khanna was born in the UK and holds dual nationality, both British and American. He studied for his bachelor's degree in biochemistry and economics in Berkeley, California, and MBA in Marketing from Santa Clara. He now lives in London with his young family.
Deepak is currently a member of the ABPI Board of Management, Chair of the ABPI HTA Taskforce and Chair of the American Pharmaceutical Group.
Commenting on Deepak’s appointment, Stephen Whitehead, CEO of the ABPI, said:
“With ongoing economic challenges, increased global competition, the largest ever patent cliff and NHS reforms, Deepak’s appointment comes at a crucial time for our industry. We have had to evolve. Our industry has changed, and I expect it to continue to change. But we are moving into a more positive era. We are working more closely with the NHS and Government than ever before; just this week David Cameron announced the Government’s support for our industry – and on top of that, the steps proposed in the Innovation Review will, if adopted, make the UK a far more inviting location for investment. We are moving in the right direction, and I very much look forward to working together with Deepak to ensure this progress continues.”
Responding to Deepak’s appointment, current ABPI President Simon Jose said:
“We are in a time of dynamic change in our industry, the economy and the health service and so I am delighted that in Deepak we have the right qualities to lead the ABPI in the forthcoming period of transition – he brings a wealth of experience and expertise to the role and will serve our members and prospective members very well as we go forward.”
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
We represent innovative research-based biopharmaceutical companies, both large and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing 90 per cent of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
We are the Government recognised body negotiating the pricing of branded medicines on behalf of the entire industry. Working with our Research Affiliate Members, we promote the UK as a destination of choice for international life sciences investment.